{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:27:42Z","timestamp":1787923662992,"version":"build-2784847793"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204520"],"award-info":[{"award-number":["82204520"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2026J0011894"],"award-info":[{"award-number":["2026J0011894"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20244Y0101"],"award-info":[{"award-number":["20244Y0101"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai \u2018Rising Stars of Medical Talent\u2019 Youth Development Program Youth Medical Talents\u2014Clinical Pharmacist Program","award":["SHWSRS (2023)106"],"award-info":[{"award-number":["SHWSRS (2023)106"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jie-ping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2024-18-12"],"award-info":[{"award-number":["320.6750.2024-18-12"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vancomycin, as a first-line treatment for methicillin-resistant staphylococcus aureus infections, is notably nephrotoxic. Research on vancomycin nephrotoxicity in patients with moderate chronic kidney disease (CKD) is still lacking. This study aims to investigate the incidence of vancomycin-associated acute kidney injury (VA-AKI) in patients with moderate CKD and to identify associated risk factors in this specific population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicentre, retrospective, cohort study from China. Patients with estimated glomerular filtration rate (eGFR) \u02c290\u2005mL\/(min\u00b71.73\u2005m2) who received vancomycin from January 2009 to December 2024 were included. For patients with moderate CKD and eGFR \u02c260\u2005mL\/(min\u00b71.73\u2005m2), multivariate logistic regression analysis was used to identify the independent risk factors for VA-AKI and the prognosis of VA-AKI patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3844 patients were included, and 1194 patients had moderate CKD. The incidence of VA-AKI in patients with moderate CKD was 19.1% (228\/1194). The risk of VA-AKI increased significantly with the progression of CKD stages (P\u200a=\u200a0.003). Cardiac insufficiency (OR 1.816, 95% CI 1.320\u20132.500, P\u200a&amp;lt;\u200a0.001), ICU admission (OR 2.018, 95% CI 1.449\u20132.810, P\u200a&amp;lt;\u200a0.001), and duration of vancomycin therapy (OR 1.482, 95% CI 1.071\u20132.051, P\u200a=\u200a0.018) were significantly and independently associated with VA-AKI in patients with moderate CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence of VA-AKI in patients with moderate CKD is slightly higher than that in mixed populations (general, unselected hospitalized cohorts). This study indicates that the risk of VA-AKI increases with the severity of CKD staging. Heart failure, ICU admission, and duration of vancomycin therapy may result in a higher risk of VA-AKI occurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag173","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:43:42Z","timestamp":1787921022000},"source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin-associated acute kidney injury in patients with moderate CKD: a multicentre retrospective cohort study"],"prefix":"10.1093","volume":"8","author":[{"given":"Liujing","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyun","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital of Naval Medical University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengchun","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital of Tongji University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University , Shanghai ,","place":["China"]},{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University (Xiamen Branch) , Xiamen, Fujian ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University , Shanghai ,","place":["China"]},{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University (Xiamen Branch) , Xiamen, Fujian ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-2939","authenticated-orcid":false,"given":"Kunming","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University , Shanghai ,","place":["China"]},{"name":"Department of Pharmacy, Zhongshan Hospital, Fudan University (Xiamen Branch) , Xiamen, Fujian ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026082805042121300_dlag173-B1","doi-asserted-by":"publisher","first-page":"e0293423","DOI":"10.1371\/journal.pone.0293423","article-title":"Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: a systematic literature review and meta-analysis","volume":"19","author":"Adamu","year":"2024","journal-title":"PLoS One"},{"issue":"1-6","key":"2026082805042121300_dlag173-B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/sjkdt.sjkdt_141_21","article-title":"Utilizing nephrotoxic medications and starting renal replacement therapies in acute settings: a single-center retrospective study","volume":"36","author":"Aljuhani","year":"2025","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2026082805042121300_dlag173-B3","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.jiac.2025.102744","article-title":"Vancomycin-associated acute kidney injury and its clinical and economic impact: a retrospective cohort study using two Japanese healthcare databases","volume":"31","author":"Murakami","year":"2025","journal-title":"J Infect Chemother"},{"key":"2026082805042121300_dlag173-B4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3760\/cma.j.cn112138-20211011-00688","article-title":"Nomogram of the area under the vancomycin curve to predict the clinical value of vancomycin-associated kidney injury in critically ill patients","volume":"61","author":"Jinlong","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2026082805042121300_dlag173-B5","doi-asserted-by":"publisher","first-page":"632107","DOI":"10.3389\/fphar.2021.632107","article-title":"Vancomycin associated acute kidney injury: a longitudinal study in China","volume":"12","author":"Kunming","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026082805042121300_dlag173-B6","doi-asserted-by":"publisher","first-page":"1260802","DOI":"10.3389\/fphar.2023.1260802","article-title":"Vancomycin associated acute kidney injury in patients with infectious endocarditis: a large retrospective cohort study","volume":"14","author":"Kunming","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026082805042121300_dlag173-B7","doi-asserted-by":"publisher","first-page":"e70485","DOI":"10.1002\/nop2.70485","article-title":"Typologies of symptoms and functions among patients with chronic kidney disease and population characteristics: a latent profile analysis","volume":"13","author":"Liu","year":"2026","journal-title":"Nurs Open"},{"key":"2026082805042121300_dlag173-B8","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026082805042121300_dlag173-B9","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.25.254","article-title":"Chronic kidney disease in Asia: a meta-analysis","author":"Chen","year":"2026","journal-title":"Kidney Res Clin Pract"},{"key":"2026082805042121300_dlag173-B10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","article-title":"Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance","volume":"183","author":"Wang","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026082805042121300_dlag173-B11","doi-asserted-by":"publisher","first-page":"573282","DOI":"10.2147\/PPA.S573282","article-title":"Development and validation of the treatment adherence scale for non-dialysis chronic kidney disease patients in China: a mixed-methods study","volume":"20","author":"Cui","year":"2026","journal-title":"Patient Prefer Adherence"},{"key":"2026082805042121300_dlag173-B12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/ejhpharm-2019-002013","article-title":"Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function","volume":"28","author":"\u0160\u00edma","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"2026082805042121300_dlag173-B13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1515\/med-2018-0068","article-title":"Pharmacokinetics of vancomycin in patients with different renal function levels","volume":"13","author":"Zaric","year":"2018","journal-title":"Open Med (Wars)"},{"key":"2026082805042121300_dlag173-B14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.cmi.2024.06.017","article-title":"Acute kidney injury in Staphylococcus aureus bacteraemia: a recurrent events analysis","volume":"30","author":"Buis","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026082805042121300_dlag173-B15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.ajkd.2013.02.349","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury","volume":"61","author":"Palevsky","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026082805042121300_dlag173-B16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0140-6736(15)00344-X","article-title":"Acute kidney injury in China: a cross-sectional survey","volume":"10002","author":"Yang","year":"2015","journal-title":"The Lancet"},{"key":"2026082805042121300_dlag173-B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"2026082805042121300_dlag173-B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3969\/j.issn.1672-3384.2021.01.003","article-title":"Interpretation of the \u201cChinese guidelines for vancomycin therapeutic drug monitoring (2020 update)\u201d","volume":"19","author":"He","year":"2021","journal-title":"J Clin Drug Ther"},{"key":"2026082805042121300_dlag173-B19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/bcp.13594","article-title":"Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study","volume":"84","author":"Pan","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026082805042121300_dlag173-B20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.36518\/2689-0216.1502","article-title":"Implementing AUC monitoring in a pharmacist-managed vancomycin dosing protocol: a retrospective cohort study","volume":"4","author":"Robinson","year":"2023","journal-title":"HCA Healthc J Med"},{"key":"2026082805042121300_dlag173-B21","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1017\/ash.2025.10181","article-title":"Effect of introducing a pharmacist-led support system on the administration rate of vancomycin loading dose and the 0-24-hour area under the concentration-time curve","volume":"5","author":"Tai","year":"2025","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026082805042121300_dlag173-B22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/antibiotics14080775","article-title":"Optimizing safety and efficacy of intravenous vancomycin therapy in orthopedic inpatients through a standardized dosing protocol: a Pre-post cohort study","volume":"14","author":"Diers","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"2026082805042121300_dlag173-B23","doi-asserted-by":"publisher","first-page":"815188","DOI":"10.3389\/fphar.2022.815188","article-title":"Risk scoring system for vancomycin-associated acute kidney injury","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026082805042121300_dlag173-B24","doi-asserted-by":"publisher","first-page":"e0156221","DOI":"10.1128\/spectrum.01562-21","article-title":"Sun evaluation of therapeutic vancomycin monitoring in Taiwan","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026082805042121300_dlag173-B25","doi-asserted-by":"publisher","first-page":"101362","DOI":"10.1016\/j.artd.2024.101362","article-title":"Acute kidney injury after total hip and knee arthroplasty. What is the culprit?","volume":"27","author":"Shahi","year":"2024","journal-title":"Arthroplast Today"},{"key":"2026082805042121300_dlag173-B26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fphar.2019.00641","article-title":"Optimizing vancomycin dosing in chronic kidney disease by deriving and implementing a web-based tool using a population pharmacokinetics analysis","volume":"10","author":"Dorajoo","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026082805042121300_dlag173-B27","doi-asserted-by":"publisher","first-page":"e70111","DOI":"10.1002\/phar.70111","article-title":"Development and validation of a novel scoring model integrating clinical risk factors and pharmacokinetic parameters to predict vancomycin-induced nephrotoxicity","volume":"46","author":"Matsuki","year":"2026","journal-title":"Pharmacotherapy"},{"key":"2026082805042121300_dlag173-B28","doi-asserted-by":"publisher","first-page":"e39202","DOI":"10.1097\/MD.0000000000039202","article-title":"Serum and urinary biomarkers of vancomycin-induced acute kidney injury: a prospective, observational analysis","volume":"103","author":"Park","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026082805042121300_dlag173-B29","doi-asserted-by":"publisher","first-page":"e0175688","DOI":"10.1371\/journal.pone.0175688","article-title":"Vancomycin-associated acute kidney injury: a cross-sectional study from a single center in China","volume":"12","author":"Pan","year":"2017","journal-title":"PLoS One"},{"key":"2026082805042121300_dlag173-B30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3870\/j.issn.1004-0781.2024.02.006","article-title":"Analysis of 1106 cases of vancomycin blood concentration monitoring and influencing factors","volume":"43","author":"Kunming","year":"2024","journal-title":"Her Med"},{"key":"2026082805042121300_dlag173-B31","doi-asserted-by":"publisher","first-page":"1370040","DOI":"10.3389\/fphar.2024.1370040","article-title":"Is it time to recommend AUC-based vancomycin therapeutic drug monitoring only? A cross-sectional survey in China","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026082805042121300_dlag173-B32","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1111\/bcp.15429","article-title":"Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis","volume":"88","author":"Kim","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026082805042121300_dlag173-B33","doi-asserted-by":"publisher","first-page":"e0284223","DOI":"10.1371\/journal.pone.0284223","article-title":"The influence of vancomycin on renal functions, the predictors and associated factors for nephrotoxicity","volume":"18","author":"Altowayan","year":"2023","journal-title":"PLoS One"},{"key":"2026082805042121300_dlag173-B34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000531511","article-title":"Vancomycin hydrochloride as a risk factor for acute kidney injury: a retrospective study","volume":"108","author":"Uekusa","year":"2023","journal-title":"Pharmacology"},{"key":"2026082805042121300_dlag173-B35","doi-asserted-by":"publisher","first-page":"3520935","DOI":"10.1155\/bmri\/3520935","article-title":"The protective effect of omeprazole on vancomycin cytotoxicity in HK-2 cells and renal injury in rats","volume":"2025","author":"Wu","year":"2025","journal-title":"Biomed Res Int"},{"key":"2026082805042121300_dlag173-B36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7150\/ijms.69807","article-title":"N-acetylcysteine Ameliorates vancomycin-induced nephrotoxicity by inhibiting oxidative stress and apoptosis in the in vivo and in vitro models","volume":"19","author":"Yu","year":"2022","journal-title":"Int J Med Sci"},{"key":"2026082805042121300_dlag173-B37","doi-asserted-by":"publisher","first-page":"e0373923","DOI":"10.1128\/spectrum.03739-23","article-title":"Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study","volume":"12","author":"Ishigo","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2026082805042121300_dlag173-B38","doi-asserted-by":"publisher","first-page":"e48627","DOI":"10.7759\/cureus.48627","article-title":"Incidence, patterns, and characteristics of patients with acute kidney injury requiring renal replacement therapy in cancer settings","volume":"15","author":"Siddiq","year":"2023","journal-title":"Cureus"},{"key":"2026082805042121300_dlag173-B39","doi-asserted-by":"publisher","first-page":"e0264281","DOI":"10.1371\/journal.pone.0264281","article-title":"Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients","volume":"17","author":"C\u00f4t\u00e9","year":"2022","journal-title":"PLoS One"},{"key":"2026082805042121300_dlag173-B40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026082805042121300_dlag173-B41","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2215\/CJN.0000000000000064","article-title":"Cardiorenal syndrome in the hospital","volume":"18","author":"McCallum","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082805042121300_dlag173-B42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3969\/j.issn.1006-4931.2024.04.028","article-title":"Analysis of risk factors for vancomycin-associated acute kidney injury and non-recovery of renal function","volume":"33","author":"Xu","year":"2024","journal-title":"China Pharm"},{"key":"2026082805042121300_dlag173-B43","doi-asserted-by":"publisher","first-page":"e0295136","DOI":"10.1371\/journal.pone.0295136","article-title":"Vancomycin nephrotoxicity: a comprehensive clinico-pathological study","volume":"19","author":"Nachiappa Ganesh","year":"2024","journal-title":"PLoS One"},{"key":"2026082805042121300_dlag173-B44","doi-asserted-by":"publisher","first-page":"e00266","DOI":"10.1016\/j.plabm.2022.e00266","article-title":"The association of high vancomycin trough concentration with acute kidney injury during combination therapy of piperacillin\/tazobactam and vancomycin","volume":"29","author":"Saito","year":"2022","journal-title":"Pract Lab Med"},{"key":"2026082805042121300_dlag173-B45","doi-asserted-by":"publisher","first-page":"e49883","DOI":"10.7759\/cureus.49883","article-title":"Impact of proton pump inhibitors on kidney function and chronic kidney disease progression: a systematic review","volume":"15","author":"Parmar","year":"2023","journal-title":"Cureus"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag173\/70826984\/dlag173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag173\/70826984\/dlag173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:44:53Z","timestamp":1787921093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag173\/8772269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag173","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag173"}}